GCP
EDIT icon

Gill Capital Partners’s Editas Medicine EDIT Stock Holding History

Gill Capital Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05K Buy
+425
New +$899 ﹤0.01% 596

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gill Capital Partners's EDIT Position: Q1 2026 in Review

Gill Capital Partners opened a new position in Editas Medicine (EDIT) in Q1 2026: 425 shares worth $1.05K. The stake represents ﹤0.01% of the portfolio and ranks #596 among its holdings.

207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Gill Capital Partners held 425 shares of Editas Medicine worth $1.05K as of Q1 2026.
  • Editas Medicine was a new Gill Capital Partners position in Q1 2026.
  • Editas Medicine made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #596 holding.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.